CHILDRENS CANCER GROUP

奥兰治县儿童医院(CHOC)最近才被批准为 儿童癌症组织(CCG)正式成员机构(1993年4月)。 尽管成为正式会员只有18个月，但CHEC调查人员 为开发新的治疗方法做出了重大贡献 议定书，建立两个参考实验室，并已 在CCG内部提供重要的科学和行政领导。 CHOC目前将所有符合条件的患者登记到CCG方案和IS 经批准的CCG第一期和骨髓移植机构。长的- 这项建议的长期目标是进一步改善 儿童癌症的预防、诊断和治疗 参与CCG。这一建议的具体目标包括：L) 在多个战略小组、纪律委员会、 和研究委员会；2)扩大参考实验室 淋巴瘤研究和造血/细胞因子翻译研究；3) 领导和实施团体第一阶段试验；和4) 开发可翻译和实施的试验性研究 集团范围内的研究。CHEC目前有7名调查人员 参加了32个委员会的任命。招聘额外的人员 CHEC调查人员将提供额外的科学和管理 CCG在战略小组层面的领导，研究主席，研究 在科学和纪律委员会内担任副主席。选择 造血/细胞因子实验室将继续研究干细胞 调控和细胞因子受体调控，开发体外研究方法 干细胞(CD34)的分离和扩增，并优化 外周干细胞动员用于重复亚清髓治疗 心理治疗。淋巴瘤参考实验室将继续调查 儿童淋巴瘤的致癌机制及替代治疗 策略，包括伯基特淋巴瘤的反义基因治疗。 生物治疗、免疫治疗和造血方面的第一阶段试点试验， 包括IL-2和活化的白细胞，IL-12+IL-15免疫治疗， 自体移植物抗宿主肿瘤的诱导，以及新细胞因子的使用， 包括血小板生成素，将在CHEC进行探索，并有可能 导致了全组范围的研究。总而言之，CHEC将继续提供 通过CCG领导试点研究，参与所有开放的CCG 第一阶段、第二阶段、第三阶段和骨髓移植研究，制定方案 以确定化疗和放疗的远期疗效 免疫疗法，并在 实验造血区和儿童淋巴瘤。

Children's Hospital of Orange County (CHOC) was only recently approved as a full member institution (April 1993) in Childrens Cancer Group (CCG). Despite being a full member for only eighteen months, CHOC investigators have contributed significantly to the development of new therapeutic protocols, the establishment of two reference laboratories, and have provided significant scientific and administrative leadership within CCG. CHOC currently registers all eligible patients on to CCG protocols and is an approved CCG phase I and Bone Marrow Transplant institution. The long- term objective of this proposal is to further the improvement in the prevention, diagnosis, and treatment of childhood cancer through participation in CCG. The specific aims of this proposal include: l) providing leadership in several strategy groups, discipline committees, and study committees; 2) expanding the reference laboratories for lymphoma studies and hematopoiesis/cytokine translational research; 3) providing leadership and implementation of group phase I trials; and 4) developing pilot studies that can be translated and implemented into groupwide studies. There are presently 7 investigators at CHOC participating in 32 committee appointments. The recruitment of additional CHOC investigators will provide additional scientific and administrative CCG leadership at the level of the strategy group, study chair, study vice chair, and within scientific and discipline committees. The CHOC Hematopoisis/Cytokine Laboratory will continue to investigate stem cell regulation and cytokine receptor modulation, develop methods for ex vivo isolation and expansion of stem cells (CD34), and optimize the mobilization of peripheral stem cells for repetitive submyeloablative therapy. The Lymphoma Reference Laboratory will continue to investigate the oncogenesis of childhood lymphomas and develop alternative treatment strategies, including antisense gene therapy for Burkitt's lymphoma. Pilot phase I trials in biotherapy, immunotherapy, and hematopoiesis, including lL-2 and activated leukocytes, IL-12 + IL-15 immunotherapy, auto-graft-vs-host tumor induction, and the use of new cytokines, including thrombopoietin, will be explored at CHOC and will potentially lead to groupwide studies. In summary, CHOC will continue to provide leadership for pilot studies through CCG, participate in all open CCG phase I, II, III, and bone marrow transplant studies, develop protocols for determining the long-term effects of chemo-radiotherapy and immunotherapy, and conduct specific biological investigations in the areas of experimental hematopoiesis and childhood lymphoma.